Hormones Induced by Pregnancy Inhibit Development of Breast Cancer
|
By HospiMedica International staff writers Posted on 07 Dec 2009 |
|
The observation that pregnancy inhibits tumor development has led cancer researchers to explore the relationship between pregnancy hormones and alpha-fetoprotein (AFP), a serum marker for fetal abnormalities.
Pregnancy is known to reduce mammary cancer risk in carcinogen-exposed rats, and administering pregnancy hormones to these animals is similarly effective. Paradoxically, pregnancy hormones are also able to stimulate cancer growth. Understanding this dichotomy was the goal of the current study undertaken by investigators at Albany Medical College (NY, USA). Their intent was to determine whether administered pregnancy hormones would elicit the cancer-inhibiting agent alpha-fetoprotein (AFP) from the liver, which would implicate AFP as a key modulator of hormonal anticancer activity. To this end they treated groups of nitrosomethylurea-exposed rats with saline, estrogen, progesterone, or human chorionic gonadotropin or allowed them to experience pregnancy. The animals were monitored for mammary cancer incidence and serum levels of AFP over time.
Results published in the November 24, 2009, online edition of the journal Cancer Prevention Research revealed that each hormone treatment reduced mammary cancer incidence and elevated serum AFP levels. AFP was shown to directly inhibit the growth of breast cancer cells growing in culture, suggesting that these hormones of pregnancy prevented breast cancer through their induction of AFP. This conclusion was strengthened by the finding that antibodies to AFP neutralized its growth-inhibiting effect.
"Hormones in pregnancy, such as estrogen, all induce AFP, which directly inhibits the growth of breast cancer,” said first author Dr. Herbert Jacobson, professor of reproductive sciences at Albany Medical College. "The body has a natural defense system against breast cancer. AFP needs to be safely harnessed and developed into a drug that can be used to protect women from breast cancer.”
Related Links:
Albany Medical College
Pregnancy is known to reduce mammary cancer risk in carcinogen-exposed rats, and administering pregnancy hormones to these animals is similarly effective. Paradoxically, pregnancy hormones are also able to stimulate cancer growth. Understanding this dichotomy was the goal of the current study undertaken by investigators at Albany Medical College (NY, USA). Their intent was to determine whether administered pregnancy hormones would elicit the cancer-inhibiting agent alpha-fetoprotein (AFP) from the liver, which would implicate AFP as a key modulator of hormonal anticancer activity. To this end they treated groups of nitrosomethylurea-exposed rats with saline, estrogen, progesterone, or human chorionic gonadotropin or allowed them to experience pregnancy. The animals were monitored for mammary cancer incidence and serum levels of AFP over time.
Results published in the November 24, 2009, online edition of the journal Cancer Prevention Research revealed that each hormone treatment reduced mammary cancer incidence and elevated serum AFP levels. AFP was shown to directly inhibit the growth of breast cancer cells growing in culture, suggesting that these hormones of pregnancy prevented breast cancer through their induction of AFP. This conclusion was strengthened by the finding that antibodies to AFP neutralized its growth-inhibiting effect.
"Hormones in pregnancy, such as estrogen, all induce AFP, which directly inhibits the growth of breast cancer,” said first author Dr. Herbert Jacobson, professor of reproductive sciences at Albany Medical College. "The body has a natural defense system against breast cancer. AFP needs to be safely harnessed and developed into a drug that can be used to protect women from breast cancer.”
Related Links:
Albany Medical College
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Blood Gas Analyzer
i-Check200
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Latest Genomics/Proteomics News
Channels
Artificial Intelligence
view channel
AI Platform Supports Noninvasive Remote Hemodynamic Monitoring in Heart Failure
Heart failure remains a leading cause of hospitalization in adults over 65, affecting more than 6.7 million people in the U.S. Clinicians often lose visibility into hemodynamic deterioration once patients... Read more
AI Tool Predicts Unplanned Care and Symptom Burden in Cancer Survivors
Unplanned emergency visits and hospitalizations remain common in cancer survivorship, when routine clinical contact often tapers while new symptoms emerge. These events reflect unmet needs and disrupt... Read more
Critical Care
view channel
Smartphone Heart Rhythm App Reduces Unnecessary Cardioversion Procedures
Atrial fibrillation, an irregular and often rapid heart rhythm, is the most common arrhythmia in adults. Elective electrical cardioversion is frequently canceled on the day of treatment when patients revert... Read more
New Practice Guidance Supports Prostatic Artery Embolization for BPH Symptoms
Benign prostatic hyperplasia is a noncancerous enlargement of the prostate that can cause lower urinary tract symptoms and impair daily functioning. These symptoms erode sleep, productivity, and sexual... Read more
Bedside CSF Monitor Detects Early Infection in Fluid Drains
External drainage of cerebrospinal fluid (CSF) after traumatic brain injury, hydrocephalus, or hemorrhage carries a significant risk of infection. These infections can prolong intensive care, cause severe... Read more
Wearable Ultrasound Patch Noninvasively Paces Heart to Stabilize Arrhythmias
Cardiac arrhythmias, including slow and irregular heart rhythms, often require pacemakers that are surgically implanted. While effective, implants carry procedural risks and long-term device maintenance burdens.... Read moreSurgical Techniques
view channel
CE-Marked Ultrasonic Shears Streamline Breast and Thyroid Surgery
Thyroid and breast surgeries are often performed in confined anatomical spaces near critical structures, making precise dissection and controlled thermal management essential. As the global disease burden... Read more
3D Map of Heart Electrical Wiring Aims to Guide Congenital Heart Repair
Tetralogy of Fallot is one of the most common congenital heart problems and often requires surgery in infancy. Many survivors later develop conduction abnormalities because the cardiac electrical system... Read more
Patient Care
view channel
AI Avatar Doctor Improves Patient Understanding Before Radiotherapy
Radiation oncology consultations require patients to grasp complex concepts quickly, yet anxiety and information overload often undermine understanding and informed consent. Poor comprehension can also... Read more
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Health IT
view channel
AI-Native EHR Achieves EU Medical Device Certification
InterSystems (Boston, MA, USA) announced that its IntelliCare electronic health record (EHR) solutions have been certified as Class IIa medical devices under the European Union Medical Device Regulation... Read more
EHR-Integrated Screening Workflow Detects Cognitive Impairment at Admission
Cognitive impairment involves difficulties with thinking, learning, memory, and decision-making, and is more common in older adults. In U.S. hospitals, more than 40% of admitted older adults have dementia,... Read more
Point of Care
view channel
Portable MRI System Accelerates Emergency Brain Imaging and Triage
Emergency departments frequently face delays accessing conventional magnetic resonance imaging (MRI) for patients with suspected neurological emergencies. Such waits can slow triage, prolong boarding,... Read more
Point-of-Care Viscoelastic Testing System Supports Obstetric Bleeding Management
HemoSonics (Durham, NC, USA) announced on May 5, 2026 that the company's Quantra Hemostasis System for Obstetric Procedures won Silver in the 2026 Edison Awards in the Women’s Health and Reproductive Innovations... Read more
Business
view channel
Endologix Adds FDA-Cleared Peripheral Thrombectomy System
Endologix (Santa Rosa, CA, USA) has acquired the Pounce Thrombectomy System from Surmodics, with the transaction closing on May 18, 2026. The FDA-cleared system is indicated for the non-surgical removal... Read more
